Company intelligence / Profile preview
Opiant Pharmaceuticals
Santa Monica, California, United Statesindivior.com ↗
- Ownership
- Public · OPNT
- Employees
- ~38
- Development stage
- Commercial
01
Overview
Opiant developed NARCAN® nasal spray—an FDA-approved treatment to reverse opioid overdoses—and advanced a pipeline focused on addiction and overdose. Its lead asset at acquisition was OPNT003, a late-stage investigational opioid overdose treatment targeting synthetic opioids like fentanyl. Other assets included a Phase II program in alcohol use disorder and a preclinical CB1 antagonist program for acute cannabinoid overdose[2][5].
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecule (e.g., naloxone hydrochloride)Peptides (for some investigational programs)Nasal spray drug delivery (Device/Drug combination)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
National Institute on Drug Abuse (NIDA)Biological Advanced Research and Development Authority (BARDA)Adapt Pharma/Emergent BioSolutions via licensing of NARCAN[2][6]
04
Financials
- Market cap
- $108.8M
- Total revenue
- $173.9M
- Enterprise value
- $89.9M
Beyond the preview
Go deeper on Opiant Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Opiant Pharmaceuticals.